ArticleInfectious diseases of poverty2024
Global, regional, and national burden of HIV-negative tuberculosis, 1990-2021: findings from the Global Burden of Disease Study 2021.
Article in Infectious diseases of poverty, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed.
- Global, regional, and national economic value of reducing amenable tuberculosis mortality.Infectious Disease Modelling · 2026Article
- Patient-Reported Perceptions and Barriers in Accessing Surgical Care in a Tertiary Healthcare Setting: A Cross-Sectional Study From Pakistan.Health science reports · 2026Article
- Global and China burden of maternal sepsis and infections: a systematic global burden of disease 2021 analysis with projections to 2036.The Journal of the Egyptian Public Health Association · 2026Article
- Unequal patterns of tuberculosis in women of reproductive age: Insights from the Global burden of disease study 2021.Infectious medicine · 2026Article
- Case report from a pediatric multidrug-resistant tuberculosis case with Tsukamurella co-infection identified by whole-genome sequencing: a diagnostic and therapeutic challenge.BMC infectious diseases · 2026Article
- The diagnostic yield of brushing versus non-brushing bronchoalveolar lavage fluid for Xpert MTB/RIF in patients with suspected tuberculosis: a prospective self-controlled study.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Epidemiological trajectories and predictive modeling of latent tuberculosis prevalence in South Asia: an in-depth global burden of disease analysis (1990-2021) with advanced forecasting to 2050.Journal of clinical tuberculosis and other mycobacterial diseases · 2026Article
- The epidemiology of tuberculosis infection and the Human Development Index (HDI) in Iran between 1990-2021: secondary analysis of the global burden of disease.BMC infectious diseases · 2026Article
- The association between dietary inflammatory index and latent tuberculosis infection: Confounding role of country of birth.Clinics (Sao Paulo, Brazil) · 2026Article
- Global, regional, and national burden of influenza-associated lower respiratory infections, 1990-2021: a systematic analysis from the Global Burden of Disease Study 2021.BMC infectious diseases · 2026Article
- Scaling-up tuberculosis preventive therapy to HIV-negative contacts of bacteriologically confirmed TB cases aged 5 years and above - Lessons from a tuberculosis preventive therapy surge activity in Zambia.PLOS global public health · 2026Article
- Multidrug resistant tuberculosis (MDR-TB) in Eritrea: a retrospective cohort analysis of mortality and associated factors (2013 - 2023).Frontiers in cellular and infection microbiology · 2026Article
- Tuberculosis burden attributable to smoking in China 1990-2021 and projections to 2040: A secondary analysis of GBD 2021 data.Tobacco induced diseases · 2026Article
- Global Burden of Tuberculosis and Drug-Resistant Subtypes Among Women of Childbearing Age from 1990 to 2021, with Projections to 2030.International journal of women's health · 2026Article
- Global, regional, and national burden of tuberculosis, 1990-2050: a systematic comparative analysis based on retrospective cross-sectional of GBD 2021 and WHO surveillance systems.International journal of surgery (London, England) · 2026Article
- Dynamics of Body Mass Index and Serum Albumin Levels Before and After the Intensive Phase of Tuberculosis Treatment.F1000Research · 2026Observational
- Changing epidemiological patterns of tuberculosis in China from 1990 to 2023: trends and future projections of drug-resistant and HIV-associated tuberculosis.Frontiers in public health · 2026Article
- The Global Economic Burden of Tuberculosis: Regional Disparities and Implications.Open forum infectious diseases · 2026Article
- Estimating the global burden of diarrhea among young children with wasting and stunting and its projection to 2050: evidence from the Global Burden of Disease 2021 study.Frontiers in pediatrics · 2026Article
- Discovery of novel InhA inhibitors through structural bioinformatics and machine learning-driven QSAR screening of natural products.Biology methods & protocols · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
backgroundTuberculosis (TB) is a major infectious disease with significant public health implications. Its widespread transmission, prolonged treatment duration, notable side effects, and high mortality rate pose severe challenges. This study examines the epidemiological characteristics of TB globally and across major regions, providing a scientific basis for enhancing TB prevention and control measures worldwide.
methodsThe ecological study used data from the Global Burden of Disease (GBD) Study 2021. It assessed new incidence cases, deaths, disability-adjusted life years (DALYs), and trends in age-standardized incidence rates (ASIRs), mortality rates (ASMRs), and DALY rates for drug-susceptible tuberculosis (DS-TB), multidrug-resistant tuberculosis (MDR-TB), and extensively drug-resistant tuberculosis (XDR-TB) from 1990 to 2021. A Bayesian age-period-cohort model was applied to project ASIR and ASMR.
resultsIn 2021, the global ASIR for all HIV-negative TB was 103.00 per 100,000 population [95% uncertainty interval (UI): 92.21, 114.91 per 100,000 population], declining by 0.40% (95% UI: - 0.43, - 0.38%) compared to 1990. The global ASMR was 13.96 per 100,000 population (95% UI: 12.61, 15.72 per 100,000 population), with a decline of 0.44% (95% UI: - 0.61, - 0.23%) since 1990. The global age-standardized DALY rate for HIV-negative TB was 580.26 per 100,000 population (95% UI: 522.37, 649.82 per 100,000 population), showing a decrease of 0.65% (95% UI: - 0.69, - 0.57 per 100,000 population) from 1990. The global ASIR of MDR-TB has not decreased since 2015, instead, it has shown a slow upward trend in recent years. The ASIR of XDR-TB has exhibited significant increase in the past 30 years. The projections indicate MDR-TB and XDR-TB are expected to see significant increases in both ASIR and ASMR from 2022 to 2035, highlighting the growing challenge of drug-resistant TB.
conclusionsThis study found that the ASIR of MDR-TB and XDR-TB has shown an upward trend in recent years. To reduce the TB burden, it is essential to enhance health infrastructure and increase funding in low-SDI regions. Developing highly efficient, accurate, and convenient diagnostic reagents, along with more effective therapeutic drugs, and improving public health education and community engagement, are crucial for curbing TB transmission.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.